July 1, 2010 - A Potential Treatment for Obesity and Weight Management - Companies Sign Marketing and Supply Agreement; Arena Eligible to Receive Over 30% of Eisai's Net Sales and $1.37 Billion in Other Payments - Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition. If approved by the Food and Drug Administration (FDA), Eisai will market and distribute lorcaserin in the United States. Arena will handle the manufacture and supply of the finished commercial product at its facility in Switzerland.
"Obesity is one of the most pressing public health issues of our day and one which cannot be overlooked,"... Eisai's Press Release - Arena Pharmaceuticals' Press Release -
